548 related articles for article (PubMed ID: 27210429)
21. Impact of intrahepatic hepatitis B DNA and covalently closed circular DNA on survival after hepatectomy in HBV-associated hepatocellular carcinoma patients.
Wang Q; Fiel MI; Luan W; Blank S; Kadri H; Kim KW; Hiotis SP
Ann Surg Oncol; 2013 Nov; 20(12):3761-70. PubMed ID: 23771248
[TBL] [Abstract][Full Text] [Related]
22. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
Boyd A; Gozlan J; Maylin S; Delaugerre C; Peytavin G; Girard PM; Zoulim F; Lacombe K
Hepatology; 2014 Aug; 60(2):497-507. PubMed ID: 24752996
[TBL] [Abstract][Full Text] [Related]
23. Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.
Lewin SR; Ribeiro RM; Avihingsanon A; Bowden S; Matthews G; Marks P; Locarnini SA; Ruxrungtham K; Perelson AS; Dore GJ
Hepatology; 2009 Apr; 49(4):1113-21. PubMed ID: 19115219
[TBL] [Abstract][Full Text] [Related]
24. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
[TBL] [Abstract][Full Text] [Related]
25. Detection of hepatitis B virus covalently closed circular DNA in paraffin-embedded and cryo-preserved liver biopsies of chronic hepatitis B patients.
Takkenberg RB; Zaaijer HL; Menting S; Weegink CJ; Terpstra V; Cornelissen M; Dijkgraaf MG; Jansen PL; Reesink HW; Beld MG
Eur J Gastroenterol Hepatol; 2010 Aug; 22(8):952-60. PubMed ID: 20150816
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA.
Wong DK; Seto WK; Cheung KS; Chong CK; Huang FY; Fung J; Lai CL; Yuen MF
Liver Int; 2017 Jul; 37(7):995-1001. PubMed ID: 27992681
[TBL] [Abstract][Full Text] [Related]
27. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy.
Sung JJ; Wong ML; Bowden S; Liew CT; Hui AY; Wong VW; Leung NW; Locarnini S; Chan HL
Gastroenterology; 2005 Jun; 128(7):1890-7. PubMed ID: 15940624
[TBL] [Abstract][Full Text] [Related]
28. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.
Lacombe K; Gozlan J; Boelle PY; Serfaty L; Zoulim F; Valleron AJ; Girard PM
AIDS; 2005 Jun; 19(9):907-15. PubMed ID: 15905671
[TBL] [Abstract][Full Text] [Related]
29. Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis.
Cheung CK; Lo CM; Man K; Lau GK
Liver Transpl; 2010 Nov; 16(11):1314-23. PubMed ID: 21031547
[TBL] [Abstract][Full Text] [Related]
30. Evidence that methylation of hepatitis B virus covalently closed circular DNA in liver tissues of patients with chronic hepatitis B modulates HBV replication.
Guo Y; Li Y; Mu S; Zhang J; Yan Z
J Med Virol; 2009 Jul; 81(7):1177-83. PubMed ID: 19475606
[TBL] [Abstract][Full Text] [Related]
31. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy.
Bourne EJ; Dienstag JL; Lopez VA; Sander TJ; Longlet JM; Hall JG; Kwiatkowski RW; Wright T; Lai CL; Condreay LD
J Viral Hepat; 2007 Jan; 14(1):55-63. PubMed ID: 17212645
[TBL] [Abstract][Full Text] [Related]
32. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.
Thompson AJ; Nguyen T; Iser D; Ayres A; Jackson K; Littlejohn M; Slavin J; Bowden S; Gane EJ; Abbott W; Lau GK; Lewin SR; Visvanathan K; Desmond PV; Locarnini SA
Hepatology; 2010 Jun; 51(6):1933-44. PubMed ID: 20512987
[TBL] [Abstract][Full Text] [Related]
33. Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection.
Huang YS; Chang SY; Sheng WH; Sun HY; Lee KY; Chuang YC; Su YC; Liu WC; Hung CC; Chang SC
PLoS One; 2016; 11(12):e0169228. PubMed ID: 28033344
[TBL] [Abstract][Full Text] [Related]
34. Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Miailhes P; Maynard-Muet M; Lebossé F; Carrat F; Bouix C; Lascoux-Combe C; Sogni P; Rey D; Barthe Y; Pol S; Cacoub P; Zoulim F; Piroth L
J Hepatol; 2014 Oct; 61(4):761-9. PubMed ID: 24882048
[TBL] [Abstract][Full Text] [Related]
35. Levels of hepatitis B virus replicative intermediate in serum samples of chronic hepatitis B patients.
Singla B; Chakraborti A; Sharma BK; Kapil S; Chawla YK; Arora SK; Das A; Dhiman RK; Duseja A
Mol Biol Rep; 2014 Jul; 41(7):4689-96. PubMed ID: 24706057
[TBL] [Abstract][Full Text] [Related]
36. Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.
Boyd A; Bottero J; Miailhes P; Lascoux-Combe C; Rougier H; Girard PM; Serfaty L; Lacombe K
J Int AIDS Soc; 2017 Feb; 20(1):21426. PubMed ID: 28362068
[TBL] [Abstract][Full Text] [Related]
37. Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus.
Boyd A; Gozlan J; Miailhes P; Lascoux-Combe C; Cam MS; Rougier H; Zoulim F; Girard PM; Lacombe K
AIDS; 2015 Sep; 29(15):1963-73. PubMed ID: 26153669
[TBL] [Abstract][Full Text] [Related]
38. Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients.
Boyd A; Piroth L; Maylin S; Maynard-Muet M; Lebossé F; Bouix C; Lascoux-Combe C; Mahjoub N; Girard PM; Delaugerre C; Carrat F; Lacombe K; Miailhes P
J Viral Hepat; 2016 Dec; 23(12):1017-1026. PubMed ID: 27486094
[TBL] [Abstract][Full Text] [Related]
39. Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity.
Suslov A; Meier MA; Ketterer S; Wang X; Wieland S; Heim MH
J Hepatol; 2021 Apr; 74(4):794-800. PubMed ID: 33188905
[TBL] [Abstract][Full Text] [Related]
40. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.
Matthews GV; Seaberg EC; Avihingsanon A; Bowden S; Dore GJ; Lewin SR; Sasadeusz J; Revill PA; Littlejohn M; Hoy JF; Finlayson R; Ruxrungtham K; Saulynas M; Locarnini S; Thio CL
Clin Infect Dis; 2013 May; 56(9):e87-94. PubMed ID: 23315316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
